Cargando…
1225. Next-Generation Sequencing in Clinical Practice: A Survey of Infectious Disease Providers
BACKGROUND: Next-generation sequencing (NGS) has emerged as a promising diagnostic tool in Infectious Diseases (ID). The platform offers high sensitivity, detecting difficult-to-isolate organisms. However, limitations remain in employing NGS broadly, including high cost, unstandardized methods, and...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776187/ http://dx.doi.org/10.1093/ofid/ofaa439.1410 |
_version_ | 1783630623165906944 |
---|---|
author | Vasishta, Shilpa Graber, Christopher J Vijayan, Tara |
author_facet | Vasishta, Shilpa Graber, Christopher J Vijayan, Tara |
author_sort | Vasishta, Shilpa |
collection | PubMed |
description | BACKGROUND: Next-generation sequencing (NGS) has emerged as a promising diagnostic tool in Infectious Diseases (ID). The platform offers high sensitivity, detecting difficult-to-isolate organisms. However, limitations remain in employing NGS broadly, including high cost, unstandardized methods, and unclear significance of many results. To date, there is no consensus on appropriate use of NGS. Here, we describe perceived utility of NGS among ID physicians at one academic medical center. METHODS: A survey exploring four clinical scenarios was disseminated electronically to ID attendings and fellows. Scenarios #1 (immunocompetent patient without localizing signs) and #2 (immunosuppressed patient with localizing signs) were followed by questions exploring likelihood of sending NGS. Scenarios #3 (immunocompetent patient with prosthetic joint infection) and #4 (immunosuppressed patient with cavitary lung lesion) were followed by questions exploring interpretation of NGS data. RESULTS: Twenty-six physicians responded. Respondents were more likely to send NGS for an immunosuppressed than an immunocompetent patient (8/26 vs. 2/26 respondents, p=0.024), with more respondents noting in the latter casethat NGS might “yield unhelpful/misleading results” (26 /26 vs. 17/23, p=0.0054) or might “not be cost-effective” (21/26 vs. 13/23, p=0.066). Those with over five years of experience tended to be more likely to send NGS (8/27 vs. 2/23 responses across two scenarios, p=0.065), noting more frequently that NGS might “yield a diagnosis not otherwise considered” (16/25 vs. 6/23 responses, p=0.0084) and“avoid painful/high-risk testing” (16/26 vs. 8/23 responses, p=0.062). In scenarios with available NGS data, nearlyhalf (21/49 responses across two scenarios) favored obtaining further diagnostics. CONCLUSION: Our results suggest that patient immunosuppression is a salient factor in determining clinical utility of NGS and that physician experience may affect utilization. While NGS is perceived as a useful adjunct to existing data to guide initial management, results are still interpreted with caution and rarely supersede more established methods for definitive diagnosis. Further study is needed to guide evidence-based NGS use. DISCLOSURES: All Authors: No reported disclosures |
format | Online Article Text |
id | pubmed-7776187 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-77761872021-01-07 1225. Next-Generation Sequencing in Clinical Practice: A Survey of Infectious Disease Providers Vasishta, Shilpa Graber, Christopher J Vijayan, Tara Open Forum Infect Dis Poster Abstracts BACKGROUND: Next-generation sequencing (NGS) has emerged as a promising diagnostic tool in Infectious Diseases (ID). The platform offers high sensitivity, detecting difficult-to-isolate organisms. However, limitations remain in employing NGS broadly, including high cost, unstandardized methods, and unclear significance of many results. To date, there is no consensus on appropriate use of NGS. Here, we describe perceived utility of NGS among ID physicians at one academic medical center. METHODS: A survey exploring four clinical scenarios was disseminated electronically to ID attendings and fellows. Scenarios #1 (immunocompetent patient without localizing signs) and #2 (immunosuppressed patient with localizing signs) were followed by questions exploring likelihood of sending NGS. Scenarios #3 (immunocompetent patient with prosthetic joint infection) and #4 (immunosuppressed patient with cavitary lung lesion) were followed by questions exploring interpretation of NGS data. RESULTS: Twenty-six physicians responded. Respondents were more likely to send NGS for an immunosuppressed than an immunocompetent patient (8/26 vs. 2/26 respondents, p=0.024), with more respondents noting in the latter casethat NGS might “yield unhelpful/misleading results” (26 /26 vs. 17/23, p=0.0054) or might “not be cost-effective” (21/26 vs. 13/23, p=0.066). Those with over five years of experience tended to be more likely to send NGS (8/27 vs. 2/23 responses across two scenarios, p=0.065), noting more frequently that NGS might “yield a diagnosis not otherwise considered” (16/25 vs. 6/23 responses, p=0.0084) and“avoid painful/high-risk testing” (16/26 vs. 8/23 responses, p=0.062). In scenarios with available NGS data, nearlyhalf (21/49 responses across two scenarios) favored obtaining further diagnostics. CONCLUSION: Our results suggest that patient immunosuppression is a salient factor in determining clinical utility of NGS and that physician experience may affect utilization. While NGS is perceived as a useful adjunct to existing data to guide initial management, results are still interpreted with caution and rarely supersede more established methods for definitive diagnosis. Further study is needed to guide evidence-based NGS use. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2020-12-31 /pmc/articles/PMC7776187/ http://dx.doi.org/10.1093/ofid/ofaa439.1410 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Poster Abstracts Vasishta, Shilpa Graber, Christopher J Vijayan, Tara 1225. Next-Generation Sequencing in Clinical Practice: A Survey of Infectious Disease Providers |
title | 1225. Next-Generation Sequencing in Clinical Practice: A Survey of Infectious Disease Providers |
title_full | 1225. Next-Generation Sequencing in Clinical Practice: A Survey of Infectious Disease Providers |
title_fullStr | 1225. Next-Generation Sequencing in Clinical Practice: A Survey of Infectious Disease Providers |
title_full_unstemmed | 1225. Next-Generation Sequencing in Clinical Practice: A Survey of Infectious Disease Providers |
title_short | 1225. Next-Generation Sequencing in Clinical Practice: A Survey of Infectious Disease Providers |
title_sort | 1225. next-generation sequencing in clinical practice: a survey of infectious disease providers |
topic | Poster Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776187/ http://dx.doi.org/10.1093/ofid/ofaa439.1410 |
work_keys_str_mv | AT vasishtashilpa 1225nextgenerationsequencinginclinicalpracticeasurveyofinfectiousdiseaseproviders AT graberchristopherj 1225nextgenerationsequencinginclinicalpracticeasurveyofinfectiousdiseaseproviders AT vijayantara 1225nextgenerationsequencinginclinicalpracticeasurveyofinfectiousdiseaseproviders |